Search - tctmd.com

Displaying 201 - 220 of 504

Sort: Relevancy | Date

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

US Administrative Healthcare Costs Are $600 Billion More Than Canada’s

Yael L. Maxwell

January 08, 2020

News Daily News

Long-term Watchman Data Reassure: CAP and CAP2 Registries

Michael O'Riordan

December 02, 2019

News Daily News

Many ASCVD Patients Skimp on CV Meds Due to Costs: US Survey

Caitlin E. Cox

November 25, 2019

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

Todd Neale

November 17, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Conference News AHA 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

Shelley Wood

November 11, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2019

Todd Neale

October 31, 2019

News Daily News

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

Michael O'Riordan

October 22, 2019

News Conference News TCT 2019

MitraClip Pricey but ‘Acceptable’ in COAPT Cost-Efficacy Analysis

Shelley Wood

September 29, 2019

News Opinion Editor's Corner TCT 2019

TCT 2019 Day Four: Costs and Quality of Life Take Center Stage

Shelley Wood

September 29, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

News Conference News ESC 2019

Another Step Forward for Genotype-Guided Prescribing After PCI: POPular Genetics

Yael L. Maxwell

September 03, 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Published Cohort

News Conference News ESC 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Yael L. Maxwell

September 03, 2019

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Shelley Wood

September 01, 2019

News Conference News ESC 2019

Increasing Oral Anticoagulation Use Tied to Less Ischemic Stroke in A-fib Patients in Italy

Todd Neale

August 31, 2019

News Daily News

Thwarted Access to PCSK9 Inhibitors Linked to Greater Risk of Major CV Events

Marcus A. Banks

July 25, 2019

News Industry News

Dassault Systèmes and the FDA Extend Collaboration to Inform Cardiovascular Device Review Process and Accelerate Access to New Treatments

July 24, 2019

News Conference News SCAI 2019

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Yael L. Maxwell

June 03, 2019

News Conference News EAS 2019

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

Michael O'Riordan

May 30, 2019

Advertisement

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

US Administrative Healthcare Costs Are $600 Billion More Than Canada’s

Long-term Watchman Data Reassure: CAP and CAP2 Registries

Many ASCVD Patients Skimp on CV Meds Due to Costs: US Survey

Dapagliflozin Has Benefits Across Heart Failure Subgroups

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

TCTMD’s Top 10 Most Popular Stories for October 2019

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

MitraClip Pricey but ‘Acceptable’ in COAPT Cost-Efficacy Analysis

TCT 2019 Day Four: Costs and Quality of Life Take Center Stage

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Another Step Forward for Genotype-Guided Prescribing After PCI: POPular Genetics

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Increasing Oral Anticoagulation Use Tied to Less Ischemic Stroke in A-fib Patients in Italy

Thwarted Access to PCSK9 Inhibitors Linked to Greater Risk of Major CV Events

Dassault Systèmes and the FDA Extend Collaboration to Inform Cardiovascular Device Review Process and Accelerate Access to New Treatments

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content